Japanese pharmaceutical companies gain approval for new stomach bacteria therapies
This approval comes as a result of Takeda's efforts to eradicate Helicobacter pylori. Each of the three therapies can be used to treat bacterial infection.
Vonosap is marketed in a blister pack that contains one tablet each of acid suppressant Takecab, Amolin -- a brand name for antibiotic amoxicillin -- and Clarith, the antibiotic clarithromycin. Vonopion is a triple-drug blister pack of one tablet each of Takecab, Amolin and Fragile, which is a brand name for metronidazole, an antibiotic and antiprotozoal medication.
Helicobacter pylori is a Gram-negative, microaerophilic bacterium. It typically infects the stomach, causing chronic gastritis and gastric ulcers.
More than half the people in the world harbor the bacterium in their upper gastrointestinal tracts, although infections happen more often in underdeveloped nations.
Organizations in this story
Takeda Pharmaceutical Company 1 Takeda Pkwy Deerfield, IL 60015